Bristol/Astra change-in-control
Executive Summary
Bristol-Myers Squibb's codevelopment and commercialization agreement with AstraZeneca for two diabetes compounds does not include change-in-control provisions, Bristol CFO Andrew Bonfield says during a Jan. 25 earnings call. Bristol has been rumored to be an acquisition candidate since the launch of Plavix generics, although the AstraZeneca partnership, announced Jan. 11, suggests that the firm plans to remain independent (1"The Pink Sheet" Jan. 15, 2007, p. 16)...
You may also be interested in...
Bristol/Astra Diabetes Deal Further Indicates Bristol Will Stay Independent
Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.